Results 121 to 130 of about 54,075 (219)

Cost-effectiveness of pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma. [PDF]

Hum Vaccin Immunother
Yu K, Xu Q.
europepmc   +1 more source

The Contribution to the Assignment of Defined Daily Dose (DDD) to Antineoplastic Drugs of the Italian Working Group on DDD

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 5, May 2026.
ABSTRACT Purpose To report the experience of the Italian Working Group on DDD (Ita‐DDD‐wg) in assigning DDDs to a list of antineoplastic agents. Methods Active substances from the ATC L01 group with no assigned DDD and reimbursed at least once during 2021 by the Italian Healthcare Service were identified.
Angela Boccia, Giulia Hyeraci, Anna Girardi, Rosa Gini, Gianluca Trifirò, Ylenia Ingrasciotta, Andrea Spini, Valentina Ientile, Elisabetta Poluzzi, Giampiero Mazzaglia, Ippazio Cosimo Antonazzo, Casula Manuela, Elena Tragni, Olivia Leoni, Arianna Mazzone, Michele Ercolanoni, Martina Zanforlini, Ursula Kirchmayer, Belleudi Valeria, Marco Finocchietti, Francesco Barone‐Adesi, Giuseppe Roberto   +21 more
wiley   +1 more source

Optimizing human FcRn mouse models to improve pharmacokinetic evaluation of antibody drug candidates. [PDF]

MAbs
Christianson G, Howard ZM, Kenney S, Lowell E, Bethur N, Roopenian D, Gonzalo-Gil E.   +6 more
europepmc   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Adjuvant Weekly Paclitaxel and Trastuzumab for HER2-Positive Early-Stage Breast Cancer with Preserved Baseline LVEF: Incidence of Cardiotoxicity and Feasibility of Simplified Cardiac Surveillance. [PDF]

Breast Cancer (Dove Med Press)
Tsunoda A, Mizuno T, Nakamori S, Ichikawa M, Tono Y, Saito K, Tawara I.   +6 more
europepmc   +1 more source

Transcriptional Reinforcement of the HER2–RAS Network in HER2‐Positive Gastric Cancer: The RUNX–SOS1 Axis in Context

Cancer Science, Volume 117, Issue 5, Page 1235-1243, May 2026.
RUNX‐dependent transcriptional control of SOS1 reinforces HER2–RAS signaling and may attenuate responses to HER2‐targeted therapies in HER2‐positive gastric cancer. ABSTRACT HER2‐positive gastric cancer represents a distinct molecular subtype characterized by chromosomal instability, variable HER2 amplification, and substantial intratumoral ...
Tatsuya Masuda, Takayoshi Watanabe, Toshinori Ozaki, Yasuhiko Kamikubo   +3 more
wiley   +1 more source

Trastuzumab-Induced Pneumonitis: A Rare but Potentially Severe Pulmonary Complication. [PDF]

Cureus
Rodríguez Sánchez MA, Verdiales Lugo AK, Aguilar Rubio JM, Olguin Guizado CA, Ortiz Jiménez JP, López Millán CO, Valenzuela Carvajal L.   +6 more
europepmc   +1 more source

Cancer Biomarker Test Utilization and Reimbursement in Australia: A National Analysis of Medicare Data

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Biomarker testing plays a critical role in precision oncology by guiding targeted therapy selection. In Australia, public reimbursement for somatic tumor biomarker tests has expanded over the past decade, yet national data on utilization patterns, equity of access, and public expenditure remain limited. We identified all cancer biomarker tests
Leping Kong, Christine Y. Lu
wiley   +1 more source

Predictive value of ALBI score and age for developing resistance to trastuzumab in HER-2-positive breast cancer patients: prediction based on a real-world case series from a single center in China. [PDF]

Front Pharmacol
Long J, Qin Y, Qi K, Li J.
europepmc   +1 more source

Clinical Pharmacology and Translational Science Considerations in the Development of Dual‐Payload Antibody Drug Conjugates

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Antibody‐drug conjugates (ADCs) have evolved in the last decade or two from carrying a single chemotherapy payload to carrying highly potent tubulin inhibitors and DNA damaging agents. While the latter have shown success in the clinic, efficacy has been constrained by therapeutic resistance, limited tumor penetration, and suboptimal immune ...
Paulien Ravenstijn, Toru Kakinuma, Salaheldin Hamed, Takeshi Kadokura, Yohei Okada, Srinivasu Poondru   +5 more
wiley   +1 more source